Revance Therapeutics (RVNC) Tops Q4 EPS by 3c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.83), $0.03 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
• Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy